A new trading day began on Tuesday, with Arcutis Biotherapeutics Inc (NASDAQ: ARQT) stock price down -4.22% from the previous day of trading, before settling in for the closing price of $15.64. ARQT’s price has ranged from $6.99 to $17.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 349.37%. Meanwhile, its annual earnings per share averaged 50.00%. With a float of $104.39 million, this company’s outstanding shares have now reached $117.85 million.
The extent of productivity of a business whose workforce counts for 342 workers is very important to gauge. In terms of profitability, gross margin is 90.27%, operating margin of -65.33%, and the pretax margin is -70.92%.
Arcutis Biotherapeutics Inc (ARQT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.01%, while institutional ownership is 102.23%. The most recent insider transaction that took place on Apr 01 ’25, was worth 151,236. Before that another transaction happened on Mar 25 ’25, when Company’s insider sold 2,171 for $17.56, making the entire transaction worth $38,131. This insider now owns 925,243 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.00% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Here are Arcutis Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach 0.30 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
The latest stats from [Arcutis Biotherapeutics Inc, ARQT] show that its last 5-days average volume of 1.8 million was inferior to 2.33 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 16.82%. Additionally, its Average True Range was 1.08.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 70.22%, which indicates a significant increase from 20.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.57% in the past 14 days, which was lower than the 75.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.09, while its 200-day Moving Average is $11.45. Now, the first resistance to watch is $15.43. This is followed by the second major resistance level at $15.88. The third major resistance level sits at $16.19. If the price goes on to break the first support level at $14.67, it is likely to go to the next support level at $14.36. Assuming the price breaks the second support level, the third support level stands at $13.91.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
With a market capitalization of 1.78 billion, the company has a total of 118,638K Shares Outstanding. Currently, annual sales are 196,540 K while annual income is -140,040 K. The company’s previous quarter sales were 71,360 K while its latest quarter income was -10,790 K.
